8-K 1 immucell8k.htm IMMUCELL CORPORATION 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: May 19, 2014 (Date of earliest event reported)
ImmuCell Corporation (Exact name of registrant as specified in its charter)
DE (State or other jurisdiction of incorporation) | 001-12934 (Commission File Number) | 01-0382980 (IRS Employer Identification Number)
56 Evergreen Drive Portland, Maine (Address of principal executive offices) |  | 04103 (Zip Code)
207-878-2770 (Registrant's telephone number, including area code)
Not Applicable (Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 –Other Events On May 19, 2014 ImmuCell Corporation (the "Company") submitted this Form 8-K to publicly disclose its Investor Presentation as of May 2014, which summarizes the Company’s business strategy. The full text of the presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 19, 2014 | IMMUCELL CORPORATION By: /s/Michael F Brigham Michael F. Brigham President and CEO

Exhibit Index
Exhibit No. Description

EX-99.1 | Investor Presentation of ImmuCell Corporation as of May 2014.